HUTCHMED (China) Limited has completed a licensing agreement granting GSK rights to develop and commercialize its investigational cancer candidate HMPL-A830 in markets outside Greater China, following the completion of customary closing requirements, including antitrust reviews. The agreement, first announced in September, covers HMPL-A830, an experimental antibody-targeted therapy conjugate (ATTC) designed to deliver a small-molecule KRAS inhibitor directly to tumors expressing the epidermal growth factor receptor (EGFR). The candidate is being developed for cancers associated with alterations in the KRAS gene, including colorectal, pancreatic, and lung cancers. The agreement gives GSK access to HMPL-A830 for development outside the retained markets, while HUTCHMED continues to oversee the initial clinical program. The candidate remains investigational, and its safety and efficacy will need to be established through clinical trials.

HMPL-A830 combines an anti-EGFR antibody with a potent, selective KRAS inhibitor payload. The approach is intended to target tumors through two mechanisms: delivering the inhibitor to EGFR-expressing cancer cells while also blocking EGFR signaling. HUTCHMED is investigating whether this dual action can improve antitumor activity while supporting more durable responses and an improved tolerability profile. The candidate entered Phase I clinical development in September 2026. The global study is evaluating HMPL-A830 in patients with unresectable, advanced, or metastatic solid tumors in China and the United States. The trial is registered on ClinicalTrials.gov under identifier NCT07718581.

Under the terms of the agreement, HUTCHMED Limited, a subsidiary of HUTCHMED, will lead the global Phase I development program. The GSK subsidiary will assume responsibility for subsequent clinical development and commercialization within its licensed territory. HUTCHMED expects to receive an upfront payment of $110 million following the deal’s closing. The company is also eligible for additional development, regulatory, and commercial milestone payments totaling up to $1.185 billion, along with tiered royalties on annual net sales. The licensed territory excludes mainland China, Hong Kong, Macau, and Taiwan, allowing HUTCHMED to retain rights in those markets.

HMPL-A830 belongs to HUTCHMED’s antibody-targeted therapy conjugate platform, which combines monoclonal antibodies with small-molecule inhibitor payloads. The company is developing the approach as an alternative to conventional antibody-drug conjugates, which typically use cytotoxic agents to kill cancer cells. According to HUTCHMED, its ATTC technology is designed to combine the tumor-targeting properties of antibodies with the activity of targeted small-molecule therapies. Preclinical studies have indicated that the combined approach can produce greater antitumor activity than either component alone, while potentially improving safety. The company believes antibody-guided delivery could help address toxicity associated with systemic exposure to small-molecule inhibitors. The platform may also offer opportunities to combine targeted agents with chemotherapy or immunotherapy, although these potential applications will require further investigation.

For more information, visit www.hutchmed.com.